Researchers may have discovered how a genetic mechanism in a common cause of Parkinson's works to destroy brain cells in patients--a finding that could help scientists develop new therapies for the devastating disease.
Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.
After a manufacturing problem irked the FDA and scared off partner GlaxoSmithKline, Impax Laboratories is resubmitting its investigational drug for Parkinson's disease, hoping it can clear an agency inspection and finally get its treatment on the market.
International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.
The Sunnyvale, CA-based Parkinson's Institute and Clinical Center and pharma company Berg are partnering to identify potential biomarkers to help diagnose and treat Parkinson's disease.
In the Journal of Medicinal Chemistry, scientists report that they've found a new compound that may offer protection against Parkinson's disease.
The healthcare burdens of aging populations have traditionally been a Western problem, but rising life expectancy in emerging markets has caused the pressures to spread around the world. In India, the co-founder of IT services firm Infosys has responded by funding a brain and computing research center to improve the health of the 100 million citizens aged over 60.
Biogen Idec is sticking close to its research home in Cambridge, MA, in its latest neurodegenerative drug development pact. The big biotech is teaming up with the neighboring Proteostasis Therapeutics on a potential new approach for attacking toxic proteins implicated in the development of Alzheimer's and Parkinson's diseases.
Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.